NYSE
23.88USD
-0.14 (-0.56%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
12.8B
P/E
—
EPS
—
Beta
0.84
52W range
20.02-27.64
Day range
23.43–24.11
Open
24.07
Prev close
24.01
Volume
1M
Avg volume
780.7K
Dividend
0.86
IPO
1996-09-17
https://www.zacks.com/stock/news/2968783/fms-q2-earnings-rise-on-care-delivery-revenues-miss-margins-expand?cid=CS-STOCKNEWSAPI-FT-analyst_blog|earnings_article-2968783 · 8/5/2026+0.40
https://seekingalpha.com/article/4921341-fresenius-medical-high-yield-utilities-like-stock-at-valuation-lows · 7/11/2026+0.90
https://www.zacks.com/stock/news/2932675/davita-expands-comprehensive-kidney-care-through-dialysis-services?cid=CS-STOCKNEWSAPI-FT-analyst_blog|quick_take-2932675 · 6/4/2026+0.20
https://www.cnbc.com/2026/02/03/gold-and-silver-rebound-after-historic-wipeout-as-analysts-say-thematic-drivers-stay-intact-.html · 2/3/2026+0.50
https://www.newsfilecorp.com/release/278188/Focus-Graphite-Engages-Independent-Trading-Group-as-Market-Maker · 12/16/2025
https://www.newsfilecorp.com/release/269799/Focus-Graphite-Announces-Marketing-and-Investor-Awareness-Campaign · 10/9/2025+0.40
https://www.zacks.com/stock/news/2755938/reasons-to-hold-fresenius-medical-stock-in-your-portfolio-for-now?cid=CS-STOCKNEWSAPI-FT-analyst_blog|rank_focused-2755938 · 9/23/2025+0.60
https://www.newsfilecorp.com/release/266408/Focus-Graphite-and-C4V-Report-Breakthrough-Early-Results-Showing-26-Improvement-in-LFP-Cathode-Density-Using-Lac-Knife-Cathode-Ultima · 9/15/2025+0.80
Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works